



## Pharmacotherapy of Neuropathic Pain

Guest Editor:

**Prof. Dr. Sergio Marques  
Borghi**

Department of Pathology,  
Center of Biological Sciences,  
Londrina State University,  
Londrina, Paraná 86057-970,  
Brazil

Deadline for manuscript  
submissions:

**20 June 2024**

### Message from the Guest Editor

Neuropathic pain represents one of the most challenging conditions in medicine due to its difficult diagnosis and management and permanent sequelae. Currently, neuropathic pain treatment encompasses tricyclic antidepressants, topical capsaicin or lidocaine, serotonin and norepinephrine reuptake inhibitors, serotonin-specific reuptake inhibitors, opioids up to interventional therapies such as epidural treatments together with a multidisciplinary team care targeting improvements in sleep, rehabilitation psychology, and exercises. However, a large proportion of patients still cannot find ways to adequately manage their pain, and the side effects of treatment are a relevant factor permeating all treatment options. In this sense, unveiling novel emerging molecules capable of shaping neuropathic pain pathology towards pain relief might be necessary to promote further research in this field.

This Special Issue aims to compile papers that address novel advances in the pharmacotherapy of neuropathic pain. We welcome the submission of many types of studies, including reviews and original preclinical and clinical articles.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)